49 related articles for article (PubMed ID: 38599654)
1. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
2. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.
den Broeder N; Verhoef L; de Man YA; Kok MR; Thurlings R; van der Weele W; van den Bemt BJ; van den Hoogen FH; van der Maas A; den Broeder AA
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599654
[TBL] [Abstract][Full Text] [Related]
4. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
den Broeder AA; Verhoef LM; Fransen J; Thurlings R; van den Bemt BJF; Teerenstra S; Boers N; den Broeder N; van den Hoogen FHJ
Trials; 2017 Aug; 18(1):403. PubMed ID: 28854956
[TBL] [Abstract][Full Text] [Related]
5. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.
Henry J; Gottenberg JE; Rouanet S; Pavy S; Sellam J; Tubach F; Belkhir R; Mariette X; Seror R;
Rheumatology (Oxford); 2018 Mar; 57(3):538-547. PubMed ID: 29267905
[TBL] [Abstract][Full Text] [Related]
6. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial.
Mariette X; Rouanet S; Sibilia J; Combe B; Le Loët X; Tebib J; Jourdan R; Dougados M
Ann Rheum Dis; 2014 Aug; 73(8):1508-14. PubMed ID: 23723317
[TBL] [Abstract][Full Text] [Related]
8. Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.
Verhoef LM; den Broeder N; Thurlings RM; van der Laan WH; van der Weele W; Kok MR; Bernelot Moens HJ; Woodworth TG; van den Bemt BJF; van den Hoogen FHJ; den Broeder AA
Lancet Rheumatol; 2019 Nov; 1(3):e145-e153. PubMed ID: 38229391
[TBL] [Abstract][Full Text] [Related]
9. How low can we go for continued dosing of rituximab in rheumatoid arthritis?
Pope JE
Lancet Rheumatol; 2019 Nov; 1(3):e134-e135. PubMed ID: 38229384
[No Abstract] [Full Text] [Related]
10. Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis.
van der Togt CJT; Ten Cate DF; van den Bemt BJF; Rahamat-Langendoen J; den Broeder N; den Broeder AA
Rheumatology (Oxford); 2023 Apr; 62(4):1627-1630. PubMed ID: 36000861
[TBL] [Abstract][Full Text] [Related]
11. Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells.
Opdam MAA; de Leijer JH; den Broeder N; Thurlings RM; van der Weele W; Nurmohamed MT; Kok MR; van Bon L; Ten Cate DF; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 Dec; 62(1):330-334. PubMed ID: 35686851
[TBL] [Abstract][Full Text] [Related]
12. Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis.
van der Togt CJT; Ten Cate DF; den Broeder N; Rahamat-Langendoen J; van den Bemt BJF; den Broeder AA
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI175-SI179. PubMed ID: 35377422
[TBL] [Abstract][Full Text] [Related]
13. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.
Kroon FPB; Najm A; Alunno A; Schoones JW; Landewé RBM; Machado PM; Navarro-Compán V
Ann Rheum Dis; 2022 Mar; 81(3):422-432. PubMed ID: 34876462
[TBL] [Abstract][Full Text] [Related]
14. (Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges.
den Broeder AA; den Broeder N; Verhoef LM
Rheumatol Adv Pract; 2021; 5(1):rkab007. PubMed ID: 33693305
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
